Horizon Therapeutics
Horizon Therapeutics plc, commonly referred to as Horizon, is a biopharmaceutical company headquartered in the United States, with significant operations across North America and Europe. Founded in 2008, Horizon focuses on developing innovative medicines for rare and rheumatic diseases, positioning itself as a leader in the industry. The company’s core products, including Tepezza and Krystexxa, are distinguished by their targeted approaches to treatment, addressing unmet medical needs in conditions such as thyroid eye disease and chronic gout. Horizon's commitment to research and development has led to notable achievements, including rapid growth and recognition within the biopharmaceutical sector. With a strong market presence, Horizon Therapeutics continues to advance its mission of improving patient outcomes through innovative therapies.
DitchCarbon Score
How does Horizon Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Horizon Therapeutics's score of 3 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Horizon Therapeutics's reported carbon emissions
Horizon Therapeutics, headquartered in the US, currently does not provide specific carbon emissions data or reduction targets. Without available figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the absence of disclosed emissions data may indicate a need for enhanced transparency in their sustainability practices. As the pharmaceutical industry increasingly prioritises climate action, Horizon Therapeutics may benefit from establishing clear reduction initiatives and aligning with industry standards to demonstrate their commitment to mitigating climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Horizon Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
